Your browser doesn't support javascript.
loading
The Effect of Eicosapentaenoic and Docosahexaenoic Acid Supplementation on Coronary Artery Calcium Progression in Subjects With Diabetes and Coronary Artery Disease: A Secondary Analysis of a Randomized Trial.
Asbeutah, Abdul Aziz; Daher, Ralph; Malik, Abdulaziz; Hariri, Essa; Alfaddagh, Abdulhamied; Elajami, Tarec K; Welty, Francine K.
Afiliação
  • Asbeutah AA; Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Daher R; Department of Internal Medicine, Cooper University Healthcare, Camden, New Jersey.
  • Malik A; Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Hariri E; Division of Cardiology, Johns Hopkins Medicine, Baltimore, Maryland.
  • Alfaddagh A; Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins School of Medicine, Baltimore, Maryland.
  • Elajami TK; Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Welty FK; Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts. Electronic address: francinewelty@gmail.com.
Am J Cardiol ; 225: 98-104, 2024 Aug 15.
Article em En | MEDLINE | ID: mdl-38885922
ABSTRACT
Higher coronary artery calcium (CAC) scores and progression of CAC are associated with higher mortality. We previously reported that subjects with coronary artery disease randomly allocated to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation or none had similar significant increases in CAC score over 30 months. Whether these findings are influenced by diabetes status is unknown. A total of 242 subjects with coronary artery disease who were on statin therapy were randomly allocated to to 1.86 g EPA and 1.5 g DHA daily or none (control). The CAC score was measured at baseline and 30-month follow-up using noncontrast, cardiac computed tomography. A significant interaction term between diabetes status and treatment arm was noted in the prediction of the CAC score (p <0.001). A total of 176 subjects (85.8% men) had no diabetes and 66 subjects (80.3% men) had diabetes. The mean age was 62.9 ± 7.9 versus 63.2 ± 7.1 years, respectively. The mean low-density lipoprotein cholesterol and median triglyceride levels were not significantly different between those without and with diabetes 77.7 ± 25.9 versus 77.1 ± 30.2 mg/100 ml, respectively, and 117.0 (78.0 to 158.0) versus 119.0 (84.5 to 201.5) mg/100 ml, respectively. Subjects with diabetes on EPA+DHA had a greater increase in CAC score than subjects with diabetes in the control group (median 380.7 vs 183.5, respectively, p = 0.021). In contrast, no difference occurred between the EPA+DHA and control groups in subjects without diabetes (175.7 vs 201.1, respectively, p = 0.41). In conclusion, EPA+DHA supplementation was associated with greater CAC progression in subjects with diabetes than subjects with diabetes in the control group over a 30-month period; whether this indicates progression of the disease burden or plaque stabilization requires further study.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article